Research and development
Each year, we invest in research and development concerning the company's healthcare activity and the number of our employees in this segment is steadily growing. Our products are based on top quality and safety standards.
We are expanding our research and development cooperation with external partners from throughout the world in scope of licensing purchase and sale and joint R&D projects.
Our own laboratory
Equipped with a full range of state-of-the-art technology, it enables development of advanced technology in solid, semi-solid and liquid formulations (including tablets, dragees, hard gelatin capsules, granules, powders, creams, ointments, gels, suspensions, syrups, drops).
Our R&D work produces innovative products. We are the first company in the world to change the availability category of meloxicam - an effective and safe analgesic - from prescription to OTC We were the first in Europe to introduce OTC medicine with 100 mg of furagin.
Collaboration with the academic community
Our projects are based on own progress and cooperation with other institutions,, including the Pharmaceutical Research Institution, the Jagiellonian Center of Innovation, the Poznan University of Technology, the Warsaw University of Technology, the Medical University of Gdańsk, and the Medical University of Łódź. In this area, we also cooperate with experts in various fields of science as well as with doctors and pharmacists.
Our own laboratory
We have our own R&D laboratory, which is equipped with state-of-the-art equipment allowing for development of advanced product technology in solid, semisolid and liquid formulations (tablets, coated tablets, dragees, hard gelatin capsules, granules, powders, creams, ointments, gels, syrups, drops).
Our innovative products
We are the first company in the world which has placed on the market a medicine with furagin in the form of suspension.
We are the first company in Poland which has registered OTC cytisine in capsules. The formulation and manufacture of Desmoxan is protected by a patent in Poland and in the United States.
The only such combination of paracetamol and ibuprofen in a pediatric dose in a suspension form in Europe.
We are the first pharmaceutical company in Europe to market a drug product containing furazidin at 100 mg in a single tablet.
We are expanding our research and development cooperation with external partners from throughout the world in scope of licensing purchase and sale and joint R&D projects.. The results of our work include Innovative products - we always strive to make sure that they offer added value to our consumers.